PL3268470T3 - Polipeptydy transpozazy i ich zastosowania - Google Patents

Polipeptydy transpozazy i ich zastosowania

Info

Publication number
PL3268470T3
PL3268470T3 PL16711096T PL16711096T PL3268470T3 PL 3268470 T3 PL3268470 T3 PL 3268470T3 PL 16711096 T PL16711096 T PL 16711096T PL 16711096 T PL16711096 T PL 16711096T PL 3268470 T3 PL3268470 T3 PL 3268470T3
Authority
PL
Poland
Prior art keywords
transposition
polypeptides
applications
transposition polypeptides
Prior art date
Application number
PL16711096T
Other languages
English (en)
Inventor
Laurence J. Cooper
Natalya BELOUSOVA
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of PL3268470T3 publication Critical patent/PL3268470T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
PL16711096T 2015-03-11 2016-03-10 Polipeptydy transpozazy i ich zastosowania PL3268470T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562131827P 2015-03-11 2015-03-11
PCT/US2016/021693 WO2016145146A1 (en) 2015-03-11 2016-03-10 Transposase polypeptides and uses thereof
EP16711096.4A EP3268470B1 (en) 2015-03-11 2016-03-10 Transposase polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
PL3268470T3 true PL3268470T3 (pl) 2021-06-14

Family

ID=55587385

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16711096T PL3268470T3 (pl) 2015-03-11 2016-03-10 Polipeptydy transpozazy i ich zastosowania

Country Status (17)

Country Link
US (4) US10570382B2 (pl)
EP (2) EP3268470B1 (pl)
JP (3) JP6775515B2 (pl)
KR (1) KR102615825B1 (pl)
CN (1) CN107532174A (pl)
AU (2) AU2016229094B2 (pl)
CA (1) CA2977818A1 (pl)
DK (1) DK3268470T3 (pl)
ES (1) ES2854675T3 (pl)
HU (1) HUE053368T2 (pl)
IL (2) IL285286B2 (pl)
MX (2) MX388517B (pl)
PL (1) PL3268470T3 (pl)
RU (2) RU2735700C2 (pl)
SG (1) SG11201707111RA (pl)
WO (1) WO2016145146A1 (pl)
ZA (1) ZA201706420B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
EP3974520A1 (en) 2013-05-14 2022-03-30 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
CA3190002A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
WO2016073629A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
EP3804741A3 (en) 2015-02-24 2021-07-14 Board of Regents, The University of Texas System Selection methods for genetically-modified t cells
CA2977818A1 (en) * 2015-03-11 2016-09-15 Board Of Regents, The University Of Texas System Transposase polypeptides and uses thereof
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
KR20180042449A (ko) 2015-09-15 2018-04-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 T 세포 수용체(tcr) 결합 항체 및 이의 용도
EP3368075B1 (en) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimeric antigen receptor molecules and uses thereof
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
EP3468994A1 (en) 2016-06-08 2019-04-17 Intrexon Corporation Cd33 specific chimeric antigen receptors
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
CA3049652A1 (en) 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
AU2018321105B2 (en) * 2017-08-21 2025-01-30 European Molecular Biology Laboratory Improved transposase polypeptide and uses thereof
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
US12404306B2 (en) 2018-03-06 2025-09-02 Precigen, Inc. Human papillomavirus vaccines and uses of the same
WO2020168086A1 (en) * 2019-02-13 2020-08-20 Geerlings Maurits W Nanocarriers for the delivery of nucleic acids and uses thereof
JP7769325B2 (ja) * 2019-07-23 2025-11-13 株式会社東芝 Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット
MX2022002747A (es) 2019-09-10 2022-04-06 Obsidian Therapeutics Inc Proteinas de fusion de ca2-il15 para regulacion ajustable.
US20230144097A1 (en) * 2020-03-30 2023-05-11 Institute Of Zoology, Chinese Academy Of Sciences Active dna transposon systems and methods for use thereof
WO2022147444A2 (en) 2020-12-30 2022-07-07 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN118638859A (zh) * 2024-05-10 2024-09-13 中国科学院动物研究所 活性dna转座子系统及其使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5925545A (en) 1996-09-09 1999-07-20 Wisconsin Alumni Research Foundation System for in vitro transposition
EP0973928B1 (en) 1997-03-11 2010-05-05 Regents Of The University Of Minnesota Dna-based transposon system for the introduction of nucleic acid into dna of a cell
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
EP1234780A1 (de) * 1999-06-02 2002-08-28 Alcan Technology & Management AG Kindersichere Verpackung für Tabletten
US8227432B2 (en) 2002-04-22 2012-07-24 Regents Of The University Of Minnesota Transposon system and methods of use
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US20060026699A1 (en) 2004-06-04 2006-02-02 Largaespada David A Methods and compositions for identification of genomic sequences
CA2692501C (en) * 2007-07-04 2017-10-10 Max-Delbrueck-Centrum Fuer Molekulare Medizin Hyperactive variants of the transposase protein of the transposon system sleeping beauty
US20100105140A1 (en) * 2008-07-16 2010-04-29 Fahrenkrug Scott C Plaice dna transposon system
EP2389435B1 (en) * 2009-01-23 2015-11-04 NsGene A/S Improved cell lines and their use in encapsulated cell biodelivery
WO2012140127A2 (en) 2011-04-13 2012-10-18 Immunicum Ab Method for priming of t cells
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
CA3247166A1 (en) 2012-10-04 2026-03-02 Research Development Foundation Serine protease molecules and therapies
EP3974520A1 (en) 2013-05-14 2022-03-30 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
CN105848484A (zh) 2013-10-25 2016-08-10 得克萨斯州大学系统董事会 用于免疫治疗的多克隆γδ T细胞
CA3190002A1 (en) 2014-02-14 2015-08-20 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
WO2015164740A1 (en) 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
WO2016073629A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
KR20170075785A (ko) 2014-11-05 2017-07-03 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포
EP3804741A3 (en) 2015-02-24 2021-07-14 Board of Regents, The University of Texas System Selection methods for genetically-modified t cells
CA2977818A1 (en) * 2015-03-11 2016-09-15 Board Of Regents, The University Of Texas System Transposase polypeptides and uses thereof
KR20180042449A (ko) 2015-09-15 2018-04-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 T 세포 수용체(tcr) 결합 항체 및 이의 용도
EP3368075B1 (en) 2015-10-27 2020-01-29 Board of Regents, The University of Texas System Chimeric antigen receptor molecules and uses thereof

Also Published As

Publication number Publication date
HUE053368T2 (hu) 2021-06-28
ZA201706420B (en) 2019-06-26
KR102615825B1 (ko) 2023-12-21
JP6970991B2 (ja) 2021-11-24
JP2018509151A (ja) 2018-04-05
KR20170125877A (ko) 2017-11-15
US10570382B2 (en) 2020-02-25
US11492604B2 (en) 2022-11-08
US12116604B2 (en) 2024-10-15
MX388517B (es) 2025-03-19
EP3268470A1 (en) 2018-01-17
MX2017011679A (es) 2018-02-09
EP3268470B1 (en) 2020-11-18
RU2020127887A (ru) 2020-10-02
US10883094B2 (en) 2021-01-05
IL254394B (en) 2021-08-31
DK3268470T3 (da) 2021-02-22
JP2022025097A (ja) 2022-02-09
HK1248757A1 (zh) 2018-10-19
RU2735700C2 (ru) 2020-11-06
AU2020202653A1 (en) 2020-05-14
US20180051265A1 (en) 2018-02-22
EP3851523A1 (en) 2021-07-21
CA2977818A1 (en) 2016-09-15
SG11201707111RA (en) 2017-09-28
ES2854675T3 (es) 2021-09-22
WO2016145146A1 (en) 2016-09-15
US20210171924A1 (en) 2021-06-10
IL254394A0 (en) 2017-11-30
AU2020202653B2 (en) 2022-03-10
IL285286B2 (en) 2023-11-01
AU2016229094B2 (en) 2020-02-06
RU2017134741A3 (pl) 2019-09-30
JP6775515B2 (ja) 2020-10-28
US20200216826A1 (en) 2020-07-09
CN107532174A (zh) 2018-01-02
JP2021035363A (ja) 2021-03-04
US20230151344A1 (en) 2023-05-18
IL285286B1 (en) 2023-07-01
MX2021014712A (es) 2022-01-18
AU2016229094A1 (en) 2017-10-05
RU2017134741A (ru) 2019-04-04
IL285286A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
IL285286A (en) Transposase polypeptides and uses thereof
IL293377A (en) Hsd17b13 variants and uses thereof
IL280863A (en) Autotaxin inhibitors and uses thereof
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
FI3494134T3 (fi) Muunneltuja polypeptidejä ja niiden käyttötapoja
DK3480213T3 (da) Syntac-polypeptider og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
PL3258951T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
DK4089113T3 (da) Polypeptider
PL3319612T3 (pl) Oksysterole i sposoby ich stosowania
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
IL254591A0 (en) Polypeptides
PL3672948T3 (pl) Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu
PL3393485T3 (pl) Kompozycje probiotyczne i ich zastosowanie
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
PL3337506T3 (pl) Kombinacje i ich zastosowania
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3256479T3 (da) 4-substituerede benzoxaborolforbindelser og anvendelser deraf
DK3245219T3 (da) Glypicanepitoper og anvendelser deraf
MA49905A (fr) Polyesteramines et polyesterquats
DK3280405T3 (da) Inhibitorer og anvendelser deraf
DK3386956T3 (da) Fumagillolderivater og polymorfer deraf
DK3303410T3 (da) Stivelsesholdige klæbesammensætninger og anvendelser deraf